1.9900
0.0000
(0.00%)
As of 8:11:46 AM GMT+1. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
31,450,109.0000
31,450,109.0000
30,936,904.0000
27,866,870.0000
24,942,204.0000
Cost of Revenue
9,273,423.0000
9,273,423.0000
8,680,490.0000
6,731,776.0000
6,256,882.0000
Gross Profit
22,176,686.0000
22,176,686.0000
22,256,414.0000
21,135,094.0000
18,685,322.0000
Operating Expense
15,160,675.0000
15,160,675.0000
15,496,781.0000
14,885,836.0000
12,628,654.0000
Operating Income
7,016,011.0000
7,016,011.0000
6,759,633.0000
6,249,258.0000
6,056,668.0000
Net Non Operating Interest Income Expense
-25,896.0000
-25,896.0000
-24,891.0000
-7,664.0000
-12,232.0000
Pretax Income
7,389,372.0000
7,389,372.0000
7,582,261.0000
6,847,096.0000
6,391,023.0000
Tax Provision
1,316,679.0000
1,316,679.0000
1,350,211.0000
1,158,972.0000
1,162,013.0000
Net Income Common Stockholders
5,873,325.0000
5,873,325.0000
6,091,390.0000
5,605,185.0000
5,159,655.0000
Diluted NI Available to Com Stockholders
5,873,325.0000
5,873,325.0000
6,091,390.0000
5,605,185.0000
5,159,655.0000
Basic EPS
1.98
--
2.04
1.88
1.73
Diluted EPS
1.98
--
2.04
1.88
1.73
Basic Average Shares
2,968,005.2500
--
2,979,301.0000
2,988,371.5000
2,988,642.5000
Diluted Average Shares
2,968,257.7500
--
2,979,630.7500
2,988,459.7500
2,988,884.2500
Total Expenses
24,434,098.0000
24,434,098.0000
24,177,271.0000
21,617,612.0000
18,885,536.0000
Net Income from Continuing & Discontinued Operation
5,873,325.0000
5,873,325.0000
6,091,390.0000
5,605,185.0000
5,159,655.0000
Normalized Income
5,846,319.3540
5,846,319.3540
6,051,884.1741
5,574,144.5774
4,887,155.9141
Interest Expense
25,896.0000
25,896.0000
24,891.0000
7,664.0000
12,232.0000
Net Interest Income
-25,896.0000
-25,896.0000
-24,891.0000
-7,664.0000
-12,232.0000
EBIT
7,415,268.0000
7,415,268.0000
7,607,152.0000
6,854,760.0000
6,403,255.0000
EBITDA
8,532,758.0000
8,532,758.0000
8,655,091.0000
7,720,231.0000
7,212,062.0000
Reconciled Cost of Revenue
9,273,423.0000
9,273,423.0000
8,680,490.0000
6,731,776.0000
6,256,882.0000
Reconciled Depreciation
1,117,490.0000
1,117,490.0000
1,047,939.0000
865,471.0000
808,807.0000
Net Income from Continuing Operation Net Minority Interest
5,873,325.0000
5,873,325.0000
6,091,390.0000
5,605,185.0000
5,159,655.0000
Total Unusual Items Excluding Goodwill
32,861.0000
32,861.0000
48,065.0000
37,365.0000
333,055.0000
Total Unusual Items
32,861.0000
32,861.0000
48,065.0000
37,365.0000
333,055.0000
Normalized EBITDA
8,499,897.0000
8,499,897.0000
8,607,026.0000
7,682,866.0000
6,879,007.0000
Tax Rate for Calcs
0.0002
0.0002
0.0002
0.0002
0.0002
Tax Effect of Unusual Items
5,855.3540
5,855.3540
8,559.1741
6,324.5774
60,555.9141
12/31/2020 - 1/6/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
002422.SZ Sichuan Kelun Pharmaceutical Co., Ltd.
28.13
-0.04%
ON4.F Ono Pharmaceutical Co., Ltd.
9.90
0.00%
4536.T Santen Pharmaceutical Co., Ltd.
1,551.50
-0.26%
600436.SS PIENTZEHUANG
202.51
+0.75%
CUP0.MU Chugai Pharmaceutical Co., Ltd.
20.00
-0.99%
4151.T Kyowa Kirin Co., Ltd.
2,324.00
+0.43%
4578.T Otsuka Holdings Co., Ltd.
8,034.00
+0.35%
600276.SS HENGRUI PHARMA
44.65
+0.02%
ALPMY Astellas Pharma Inc.
9.75
+1.56%
NOV.F Novo Nordisk A/S
82.66
-1.95%